May 12, 2020 / 10:14 PM / in 15 days

BRIEF-Aerpio Pharmaceuticals Says Announced Restructuring Of Licensing Deal With Unit Of Gossamer Bio

May 12 (Reuters) - Aerpio Pharmaceuticals Inc:

* AERPIO ANNOUNCES AMENDED LICENSING DEAL WITH GOSSAMER BIO ON ITS INFLAMMATORY BOWEL DISEASE (IBD) PRODUCT CANDIDATE GB004 (FORMERLY AKB-4924)

* AERPIO PHARMACEUTICALS INC - ANNOUNCED A RESTRUCTURING OF LICENSING DEAL WITH UNIT OF GOSSAMER BIO

* AERPIO - TERMS OF AMENDED AGREEMENT INCLUDE $15 MILLION IMMEDIATE PAYMENT TO CO, $90 MILLION IN MILESTONE PAYMENTS REGARDING REGULATORY APPROVALS, COMMERCIAL SALES

* AERPIO PHARMACEUTICALS - ALSO ELIGIBLE TO RECEIVE TIERED ROYALTIES ON SALES OF LICENSED PRODUCTS AT PERCENTAGES RANGING FROM LOW TO MID-SINGLE DIGITS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below